Mounting evidence suggests that oncogenic KRAS drives PDA progression through diverse mechanisms, including metabolic re-adaptations 41–44, immune suppression 45–47, and subtype differentiation 39,48. Here, KRAS is linked to Patent ductus arteriosus.